|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| A61K 38/20 | (2006.01) | ||
| A61P 19/06 | (2006.01) | ||
| A61P 19/02 | (2006.01) |
| (11) | Number of the document | 2124997 |
| (13) | Kind of document | T |
| (96) | European patent application number | 07839723.9 |
| Date of filing the European patent application | 2007-10-19 | |
| (97) | Date of publication of the European application | 2009-12-02 |
| (45) | Date of publication and mention of the grant of the patent | 2012-08-08 |
| (46) | Date of publication of the claims translation | 2012-10-25 |
| (86) | Number | PCT/US2007/022377 |
| Date | 2007-10-19 |
| (87) | Number | WO 2008/051496 |
| Date | 2008-05-02 |
| (30) | Number | Date | Country code |
| 853385 P | 2006-10-20 | US |
| (72) |
VICARY, Catherine, US
MELLIS, Scott, US
|
| (73) |
Regeneron Pharmaceuticals, Inc.,
777 Old Saw Mill Road, Tarrytown, NY 10591,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | IL-1 antagonistų panaudojimas podagros ir pseudopodagros gydymui |
| USE OF IL-1 ANTAGONISTS TO TREAT GOUT AND PSEUDOGOUT |
| Payment date | Validity (years) | Amount | |
| 2020-09-17 | 14 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2021-10-25 |